Oncolytic viral therapy with a combination of HF10, a herpes simplex virus type 1 variant and granulocyte–macrophage colony‐stimulating factor for murine ovarian cancerFumi Goshima, Yukihiro Nishiyama|International Journal of Cancer|2013Cited by 34
Phase I trial of intratumoral therapy using HF10, an oncolytic HSV-1, demonstrates safety in HSV+/HSV- patients with refractory and superficial cancers.Robert L. Ferris, Yukihiro Nishiyama, John Nemunaitis et al.|Journal of Clinical Oncology|2014Cited by 30
Herpes simplex virus induces the marked up-regulation of the zinc finger transcriptional factor INSM1, which modulates the expression and localization of the immediate early protein ICP0Maki Kamakura, Yukihiro Nishiyama|Virology Journal|2011Cited by 9